HER2/neu-Amplified Breast Cancers with HER2/CEP17 ratio ≥ 2.0 but with an Average HER2 Copy Number <4.0 Signals/Cell: An Assessment of Frequency, Immunohistochemical Correlation, and Clinicopathologic Features

被引：0
|
作者：
Zare, Somaye [1 ]
Lin, Leo [1 ]
Alghamdi, Abrar G. [2 ]
Roma, Andres [2 ]
Dell'Aquila, Marie [1 ]
Hasteh, Farnaz [2 ]
Fadare, Oluwole [1 ]
机构：
[1] UC San Diego Hlth, San Diego, CA USA
[2] Univ Calif San Diego, San Diego, CA 92103 USA
来源：
MODERN PATHOLOGY | 2018年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
328
引用
收藏
页码：117 / 117
页数：1
相关论文
共 50 条
  • [41] HER2/Neu Gene Amplification Heterogeneity: The Significance of Cells with a 3:1 HER2/CEP17 Ratio
    Layfield, L. J.
    Schmidt, R.
    MODERN PATHOLOGY, 2012, 25 : 49A - 49A
  • [42] Association between HER2 positivity by HER2/CEP17 ratio and response to neoadjuvant HER2 targeted therapy.
    Rappazzo, Katherine Cynthia
    Chen, Heidi
    Ballinger, Tarah Jean
    Abramson, Vandana Gupta
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [43] Comparative Pathologic Analysis of Breast Cancers Classified as HER2/neu-Amplified by FISH using a Standard HER2/CEP17 Dual Probe and an Alternative HER2/LIS1 Dual Probe: An Analysis of 1201 Cancers.
    Zare, Somaye
    Lin, Leo
    Alghamdi, Abrar G.
    Roma, Andres
    Hasteh, Farnaz
    Dell'Aquila, Marie
    Fadare, Oluwole
    MODERN PATHOLOGY, 2018, 31 : 117 - 117
  • [44] Relationship between pathological features, HER2 protein expression and HER2 and CEP17 copy number in breast cancer: biological and methodological considerations
    Lambein, Kathleen
    Praet, Marleen
    Forsyth, Ramses
    Van den Broecke, Rudy
    Braems, Geert
    Matthys, Bart
    Cocquyt, Veronique
    Denys, Hannelore
    Pauwels, Patrick
    Libbrecht, Louis
    JOURNAL OF CLINICAL PATHOLOGY, 2011, 64 (03) : 200 - 207
  • [45] Relationship between Pathological Features, Her2 Protein Expression, and HER2 and CEP17 Copy Numbers in DCIS.
    Lambein, K.
    Van Bockstal, M.
    Praet, M.
    Denys, H.
    Braems, G.
    Nuyts, A.
    Cocquyt, V.
    Pauweis, P.
    Van Den Broecke, R.
    Libbrecht, L.
    CANCER RESEARCH, 2011, 71
  • [46] Frequency and Clinicopathologic Features of Hormone Receptor Positive Her2/neu-Amplified Breast Cancer ("Triple Positive Breast Cancers")
    Badarane, Deyze
    Rong, Juan
    Hasteh, Farnaz
    Fadare, Oluwole
    Zare, Somaye
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 105 - 106
  • [47] Frequency and Clinicopathologic Features of Hormone Receptor Positive Her2/neu-Amplified Breast Cancer ("Triple Positive Breast Cancers")
    Badarane, Deyze
    Rong, Juan
    Hasteh, Farnaz
    Fadare, Oluwole
    Zare, Somaye
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 105 - 106
  • [48] Breast Cancer With HER2 Immunohistochemical Score 2 and Average HER2 Signals/Cell 6 or More and HER2/CEP17 Ratio Less Than 2 ('ISH Group 3'): A Multiinstitutional Cohort Analysis Emphasizing Outcome and Molecular Subtype
    Ajabnoor, Rana
    Zhang, Gloria
    Hu, Yan
    Gao, Yuan
    Finkelman, Brian S.
    Turner, Bradley M.
    Yi, Sha
    Dhakal, Ajay
    Audeh, William
    Li, Zaibo
    Li, Xiaoxian
    Hicks, David G.
    Zhang, Huina
    MODERN PATHOLOGY, 2024, 37 (08)
  • [49] The prognostic importance of high HER2 copy numbers and high HER2/CEP17 ratio in trastuzumab-treated early breast cancer
    Ronnlund, C.
    Robertson, S.
    Sifakis, E. G.
    Fredriksson, I.
    Foukakis, T.
    Hartman, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S614 - S614
  • [50] Discordance between HER2 Copies/Cell and HER2/CEP17 Ratio by Fluorescence In Situ Hybridization (FISH) in Invasive Breast Carcinoma
    Czapla, A.
    Silverman, J. F.
    Krishnamurti, U.
    MODERN PATHOLOGY, 2014, 27 : 43A - 43A
12345